Godavari Drugs Ltd (530317) — FY26 Annual Report | 1 September 2026

Godavari Drugs Limited reported FY 2025-26 revenue of ₹10,580.81 crores, down from ₹11,335.01 crores in the prior year, with PAT declining to ₹408.91 lakhs from ₹438.00 lakhs. The company highlighted progress on its new manufacturing facility, expansion into nutraceuticals via a proposed amendment to its Memorandum of Association, and continued focus on CDMO/CMO partnerships. Management emphasized strategic diversification, export growth, and operational efficiency amid industry pricing pressures. No dividend was recommended. The 38th AGM is scheduled for September 25, 2026, via video conferencing, with remote e-voting from September 22-24, 2026. Key risks include geopolitical tensions, raw material price volatility, and regulatory changes. Forward guidance focuses on commercializing new products, scaling manufacturing, and expanding global footprint.